Skip to content
ESPT
MARKETS / BALCAO / Health care / Medical devices and instruments / SCND
BALCAO · LABORATORY ANALYTICAL INSTRUMENTS · SMALL CAP

Scientific Industries Inc. SCND

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.1M
▲ 5.4% YoY
$-1.2M
$-8.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company’s products are used primarily for research purposes by universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other industries performing laboratory-scale research. On August 7, 2025, the Company sold its Genie product line which was part of the Benchtop Laboratory Equipment operations but continues to market and produce scales and pill counters in the Benchtop Laboratory Equipment operating segment. The Company designs and develops substantially all of its products in-house. The Company is investing significantly in the product development of its Bioprocessing Systems Operations with a view to generating meaningful revenues from its Bioprocessing Systems Operations in the future. Sales to one customer, principally of the VIVID® Pill counter, represented 31% and 23% of the Company’s consolidated net revenues for the years ended December 31, 2025 and 2024, respectively.

Written from the business description in Scientific Industries, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth

USD 5.1M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 5.1 · Net income -1.2
5M10M-5M-10M
201020132016201920232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−35 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -156.1% · Net -35.2%
-50%-100%-150%
201020172025
ROE
FY2025 · ROE -12.3%
5%10%-20%-40%-60%
201020172025
Three returns, three denominators.
Gross margin25.8%
Operating margin-156.1%
Net margin-35.2%
EBITDAUSD -7.6M

Each USD of equity lost 12 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.2
0.4M0.8M-3.0M-6.0M
201020172025
Net buybacks $ Dividends $
FY2011 · Dividends 59800.0 · Net buybacks ·
50000100000
20102011
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 12.6M
EquityUSD 10.7M
CashUSD 955,000.00
Current ratio7.70×

Equity funds 85% of total assets.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SCND, 15-year financial record
Metric 202520242023202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.00.0−0.0−0.00.00.00.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.00.00.00.00.00.00.00.00.00.0
Income tax $B0.00.00.00.0−0.0−0.00.00.0−0.00.0−0.0−0.00.0−0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.00.00.0−0.00.00.00.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.00.00.00.00.00.0−0.00.00.00.0
EPS, diluted $−0.11−0.61−1.27◌−1.00−0.460.43−0.11−0.050.110.01−0.050.300.050.19
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %—————————————9047
ROE %−12.3−56.0−65.4−62.5−19.4−7.810.7−2.8−1.22.80.2−1.47.61.44.9
Shares out B0.010.010.010.010.010.000.000.000.000.000.000.000.00◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 2 failures in 74 reconciliationsAUDITED

Reconciled in 13 of the 15 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures
ActivityLaboratory Analytical Instruments
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image